114 Per Cent Returns: Multibagger Pharma Company Reports 81 Per Cent PAT Growth; Sales Up 9 Per Cent
The company's net profit surged 81 per cent year-on-year (YoY) to Rs 276.4 crore, compared to Rs 152.9 crore in Q3 FY24.
Ipca Laboratories Ltd delivered a strong performance in Q3 FY25, with notable improvements in profitability and revenue growth. The company's net profit surged 81 per cent year-on-year (YoY) to Rs 276.4 crore, compared to Rs 152.9 crore in Q3 FY24. Revenue grew by 9 per cent YoY to Rs 2,245.4 crore, up from Rs 2,052.9 crore in the corresponding quarter last year.
Financial Performance
Ipca Laboratories saw a 40 per cent YoY jump in EBITDA, reaching Rs 463 crore in Q3 FY25, compared to Rs 331 crore in Q3 FY24. The earnings per share (EPS) also rose 38 per cent YoY to Rs 9.78, up from Rs 7.09 in the previous year.
Stock Performance
Ipca Laboratories’ stock has delivered 30.32 per cent returns in the past year, significantly outperforming the Nifty's 6.73 per cent rise during the same period. Over a five-year period, the stock has given 114.1 per cent returns to its investors. The company's current market capitalization stands at Rs 36,036 crore.
DSIJ's DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, do download the service details here.
About the Company
Established in 1949, Ipca Laboratories Ltd is one of India’s top 20 pharmaceutical companies, engaged in the manufacturing and marketing of over 350 formulations and 80 APIs across various therapeutic segments. The company has 18 manufacturing units across India catering to global markets, with a strong presence in Pain, Rheumatology, Antimalarials, and Hair Care therapy.
Ipca’s products are exported to over 100 countries worldwide, further solidifying its position as a global player. However, three of its manufacturing facilities remain under a US FDA import alert.
Disclaimer: This article is for informational purposes only and not an investment advice.